WO1999057284A3 - Attenuated influenza viruses - Google Patents
Attenuated influenza viruses Download PDFInfo
- Publication number
- WO1999057284A3 WO1999057284A3 PCT/GB1999/001413 GB9901413W WO9957284A3 WO 1999057284 A3 WO1999057284 A3 WO 1999057284A3 GB 9901413 W GB9901413 W GB 9901413W WO 9957284 A3 WO9957284 A3 WO 9957284A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- attenuated
- protein
- influenza virus
- attenuated influenza
- coding sequence
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16041—Use of virus, viral particle or viral elements as a vector
- C12N2760/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU37230/99A AU3723099A (en) | 1998-05-06 | 1999-05-06 | Attenuated influenza viruses |
JP2000547239A JP2002513575A (en) | 1998-05-06 | 1999-05-06 | Attenuated influenza virus |
CA002327584A CA2327584A1 (en) | 1998-05-06 | 1999-05-06 | Attenuated influenza viruses |
EP99919444A EP1075524A2 (en) | 1998-05-06 | 1999-05-06 | Attenuated influenza viruses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9809666.2A GB9809666D0 (en) | 1998-05-06 | 1998-05-06 | Modified viruses |
GB9809666.2 | 1998-05-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999057284A2 WO1999057284A2 (en) | 1999-11-11 |
WO1999057284A3 true WO1999057284A3 (en) | 1999-12-29 |
Family
ID=10831535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/001413 WO1999057284A2 (en) | 1998-05-06 | 1999-05-06 | Attenuated influenza viruses |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1075524A2 (en) |
JP (1) | JP2002513575A (en) |
AU (1) | AU3723099A (en) |
CA (1) | CA2327584A1 (en) |
GB (1) | GB9809666D0 (en) |
WO (1) | WO1999057284A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9913892B2 (en) | 2005-04-21 | 2018-03-13 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7465574B2 (en) | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
US6830748B1 (en) | 1997-09-26 | 2004-12-14 | Medimmune Vaccines, Inc. | Recombinant RSV virus expression systems and vaccines |
US11865172B2 (en) | 2005-04-21 | 2024-01-09 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
JP2009512449A (en) * | 2005-10-19 | 2009-03-26 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | Materials and methods for respiratory disease management in dogs |
WO2010144797A2 (en) | 2009-06-12 | 2010-12-16 | Vaccine Technologies, Incorporated | Influenza vaccines with enhanced immunogenicity and uses thereof |
JP2013522231A (en) | 2010-03-11 | 2013-06-13 | イミューン デザイン コーポレイション | Vaccine for influenza |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0704533A1 (en) * | 1994-09-30 | 1996-04-03 | Bayer Ag | An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus |
-
1998
- 1998-05-06 GB GBGB9809666.2A patent/GB9809666D0/en not_active Ceased
-
1999
- 1999-05-06 EP EP99919444A patent/EP1075524A2/en not_active Withdrawn
- 1999-05-06 JP JP2000547239A patent/JP2002513575A/en not_active Withdrawn
- 1999-05-06 CA CA002327584A patent/CA2327584A1/en not_active Abandoned
- 1999-05-06 WO PCT/GB1999/001413 patent/WO1999057284A2/en not_active Application Discontinuation
- 1999-05-06 AU AU37230/99A patent/AU3723099A/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0704533A1 (en) * | 1994-09-30 | 1996-04-03 | Bayer Ag | An attenuated vaccination virus, a method to make the virus and a pharmaceutical compositions comprising the virus |
Non-Patent Citations (3)
Title |
---|
BERGMANN M AND MUSTER T: "The relative amount of influenza A virus segment present in the viral particle is not affected by a reduction in replication of that segment", JOURNAL OF GENERAL VIROLOGY, vol. 76, no. 12, December 1995 (1995-12-01), READING GB, pages 3211 - 3215, XP002112523 * |
FODOR E ET AL.: "Attenuation of influenza A virus mRNA levels by promoter mutations", JOURNAL OF VIROLOGY, vol. 72, no. 8, August 1998 (1998-08-01), AMERICAN SOCIETY FOR MICROBIOLOGY US, pages 6283 - 6290, XP002112525 * |
KIM H-J ET AL: "Mutational analysis of the RNA-fork model for the influenza A virus vRNA promoter in vivo", JOURNAL OF GENERAL VIROLOGY, vol. 78, no. 2, February 1997 (1997-02-01), READING GB, pages 353 - 357, XP002112524 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9913892B2 (en) | 2005-04-21 | 2018-03-13 | University Of Florida Research Foundation, Inc. | Materials and methods for respiratory disease control in canines |
Also Published As
Publication number | Publication date |
---|---|
WO1999057284A2 (en) | 1999-11-11 |
JP2002513575A (en) | 2002-05-14 |
GB9809666D0 (en) | 1998-07-01 |
AU3723099A (en) | 1999-11-23 |
CA2327584A1 (en) | 1999-11-11 |
EP1075524A2 (en) | 2001-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY117686A (en) | Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof | |
BRPI0309631A8 (en) | tetravalent dengue vaccine containing a trivial deletion of 30 nucleotides in the utr-31 'of dengue types 1,2,3 and 4, or chimeric dengue antigenic viruses 1,2,3 and 4 | |
WO2000003030A3 (en) | Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species | |
EP1394259A3 (en) | Recombinant infectious non-segmented negative strand RNA virus | |
BR9712138A (en) | Isolated RNA virus, vaccine, process to immunize an individual to induce protection against a non-segmented, negative, single-stranded RNA virus of the mononegaviral order and to produce RNA virus, isolated nucleic acid molecule and composition. | |
BR9812232A (en) | Human respiratory syncytial virus (rsv) human subgroup b, isolated, recombinantly generated, attenuated, vaccine, process to immunize an individual to induce protection against rsv subgroup b, composition, process to produce attenuated infectious rsv subgroup b, and isolated acid molecule nucleic | |
HK1047302B (en) | Recombinant newcastle disease virus rna expression system and vaccines | |
ZA200007403B (en) | Attenuated negative strand viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals. | |
YU37502A (en) | Infectious clones | |
WO2003023040A3 (en) | Vaccinia virus mva-e3l-knockout-mutants and use thereof | |
MXPA03000061A (en) | Manipulation of negative stranded rna viruses by rearrangement of their genes and uses thereof. | |
WO1999057284A3 (en) | Attenuated influenza viruses | |
AU5460900A (en) | Infectious cdna clone of gb virus b and uses thereof | |
EP1427443A4 (en) | Vaccine using papilloma virus e proteins delivered by viral vector | |
WO2002008436A3 (en) | Mini-adenoviral vector system for vaccination | |
WO1998024912A3 (en) | Recombinant plague vaccine | |
WO1993025707A3 (en) | Methods for amplification of genome and mixtures of initiator oligonucleotides for the detection and identification of related genomic sequences | |
HUP9904201A1 (en) | Transfecting composition usable in gene therapy combining a recombinant virus incorporating an exogenous nucleic acid, a non-viral and non-plasmid transfecting agent | |
WO2002083896A3 (en) | Recombinant segmented negative strand virus with a duplicated 3' noncoding flanking sequence, and therapeutic compositions containing the same | |
HUP0103871A2 (en) | Recombinent celo virus and celo virus dna | |
MD2149G2 (en) | Oligonucleotide primer for hepatitis C virus RNA detection | |
EP0997529A3 (en) | Feline immunodeficiency virus strain FIV-141 and uses thereof | |
WO2002061048A3 (en) | In vitro system for replication of rna-dependent rna polymerase (rdrp) viruses | |
AU3955400A (en) | The full gene sequence of the donkey leukocyte vaccine strain of the equine infectious anemia virus and their application | |
PT1254663E (en) | ANTIVIRAL AGENT |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2327584 Country of ref document: CA Ref country code: CA Ref document number: 2327584 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 37230/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999919444 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999919444 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09674892 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999919444 Country of ref document: EP |